Overview:

Summary

GBI Research has released its latest research “Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns”, which essentially provides insights on lifestyle disorders therapeutics sales and price forecasts until 2016. The report also examines the global lifestyle disorders therapies treatment usage patterns. In addition, the geographical distribution of lifestyle disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the lifestyle disorders Research and Development (R&D) pipeline and the potential future blockbusters up to 2016. The report provides an in-depth analysis of the top five lifestyle disorders therapeutic indications, which are erectile dysfunction, obesity, alopecia, smoking cessation and alcohol dependence. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving lifestyle disorders therapies is also presented.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research’s analysis showed that the global lifestyle disorders therapeutics market was segmented into five indications namely erectile dysfunction with the market size of $3.2 billion in 2009, followed by obesity, alopecia, smoking cessation and finally the alcohol dependence market.

Scope

The scope of this report includes -
- Annualized market data for the lifestyle disorders therapeutics market from 2001 to 2009, with forecasts to 2016.
- Market analysis for the five major indications in the global lifestyle disorders therapeutics market which includes Erectile dysfunction, Obesity, Alopecia, Smoking Cessation and Alcohol dependence.
- Data and analysis on the lifestyle disorders therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- The competitive landscape of the global lifestyle disorders therapeutics market
- Key M&A activities and licensing agreements that took place from 2004 to 2010 in the lifestyle disorders therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Companies Mentioned

Eli Lilly
Bayer
VIVUS Inc
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
GlaxoSmithKline
Shire Plc
Pfizer
Novartis
Teva Pharmaceuticals
Watson Pharmaceuticals
Merck & Co
Johnson & Johnson
Orexigen Therapeutics, Inc
Takeda Pharmaceutical Company Limited
7TM Pharma

1 Table of Contents 3
1.1 List of Tables 7
1.2 List of Figures 10
2 Lifestyle Disorders Market – Introduction 12
2.1 GBI Research Report Guidance 13
3 Global Erectile Dysfunction Therapeutics Market 14
3.1 Market Overview 14
3.1.1 Market Forecasts 14
3.1.2 Annual Cost of Therapy 16
3.2 Treatment Usage Patterns 17
3.2.1 Diseased Population 19
3.2.2 Treatment Seeking Population 21
3.2.3 Diagnosis Population 23
3.2.4 Prescription Population 25
3.3 Geographical Segmentation 27
3.3.1 Market Share Analysis 27
3.4 Product Analysis 28
3.4.1 Viagra (sildenafil citrate) 28
3.4.2 Cialis (tadalafil) 28
3.4.3 Levitra (verdenafil HCL) 29
3.4.4 Caverject (Alprostadil) 29
3.4.5 Muse (alprostadil) 29
4 Global Obesity Therapeutics Market 30
4.1 Market Overview 30
4.1.1 Market Forecasts 30
4.1.2 Annual Cost of Therapy 32
4.2 Treatment Usage Patterns 33
4.2.1 Diseased Population 35
4.2.2 Treatment Seeking Population 36
4.2.3 Diagnosis Population 37
4.2.4 Prescription Population 38
4.3 Geographical Segmentation 39
4.3.1 Market Share Analysis 39
4.3.2 Market Forecast- US, EU-5, Japan 40
4.4 Product Analysis 42
4.4.1 Xenical (Orlistat 120mg) and Alli (Orlistat 60mg) 42
4.4.2 Bontril PDM (Phendimetrazine Tartarate) 43
4.4.3 Benzphetamine hydrochloride 43
5 Global Alopecia Therapeutics Market 44
5.1 Market Overview 44
5.1.1 Market Forecasts 45
5.1.2 Annual Cost of Therapy 46
5.2 Geographical Segmentation 47
5.2.1 Market Share Analysis 47
5.2.2 Market Forecast- US, EU-5, Japan 48
5.3 Product Analysis 49
5.3.1 Propecia (Finasteride) 49
5.3.2 Rogaine (Minoxidil) 49
5.4 Global Areata Alopecia Market 50
5.4.1 Market Overview 50
5.4.2 Market Forecasts 52
5.4.3 Annual Cost of Therapy 53
5.4.4 Treatment Usage Patterns 54
5.4.5 Geographical Segmentation 60
5.5 Global Androgenetic Alopecia Market 62
5.5.1 Market Overview 62
5.5.2 Market Forecasts 64
5.5.3 Annual Cost of Therapy 65
5.6 Treatment Usage Patterns 66
5.6.1 Diseased Population 68
5.6.2 Treatment Seeking Population 69
5.6.3 Diagnosis Population 70
5.6.4 Prescription Population 71
5.6.5 Geographical Segmentation 72
6 Global Smoking Cessation Market 74
6.1 Market Overview 74
6.1.1 Market Forecasts 74
6.1.2 Annual Cost of Therapy 76
6.2 Treatment Usage Patterns 77
6.2.1 Diseased Population 79
6.2.2 Treatment Seeking Population 80
6.2.3 Diagnosis Population 81
6.2.4 Prescription Population 82
6.3 Geographical Segmentation 83
6.3.1 Market Share Analysis 83
6.3.2 Market Forecast – US, EU-5, Japan 84
6.4 Product Analysis 85
6.4.1 Zyban(buproprion hydrochloride) 85
6.4.2 Nicotrol 85
6.4.3 Nicoderm 85
6.4.4 Nicorette 86
6.4.5 Chantix (varenicline tartarate) 86
7 Global Alcohol Dependence Market 87
7.1 Market Overview 87
7.1.1 Market Forecasts 88
7.1.2 Annual Cost of Therapy 90
7.2 Treatment Usage Patterns 91
7.2.1 Diseased Population 93
7.2.2 Treatment Seeking Population 94
7.2.3 Diagnosis Population 95
7.2.4 Prescription Population 96
7.3 Geographical Segmentation 97
7.3.1 Market Share Analysis 97
7.3.2 Market Forecast – US, EU-5, Japan 98
7.4 Product Analysis 99
7.4.1 Campral (acamprosate calcium) 99
7.4.2 Antabuse (disulfurum) 99
8 Global Lifestyle Disorders Therapeutics Market – Pipeline Analysis 100
8.1 Global Erectile Dysfunction Therapeutics Market 100
8.1.1 Major Pipeline Products by Phase 100
8.1.2 Major Late Stage Pipeline Molecules 101
8.2 Global Obesity Therapeutics Market 105
8.2.1 Pre-clinical and Discovery Phase 105
8.2.2 Phase I 108
8.2.3 Phase II 109
8.2.4 Phase III 111
8.2.5 Major Late Stage Pipeline Molecules 112
8.2.6 Victoza (liraglutide) 112
8.3 Global Alopecia Therapeutics Market 113
8.3.1 Major Late Stage Pipeline Molecules 113
8.4 Global Smoking Cessation Therapeutics Market 114
8.4.1 Pre-clinical and Discovery Phase 114
8.4.2 Phase I 114
8.4.3 Phase II 115
8.4.4 Phase III 116
8.4.5 Major Late Stage Pipeline Molecules 117
8.5 Global Alcohol Dependence Therapeutics Market 118
8.5.1 Phase I 118
8.5.2 Phase II 119
8.5.3 Phase III 121
8.5.4 Major Late Stage Pipeline Molecules 122
8.5.5 Nalfemene 122
8.5.6 NS11 123
9 Global Lifestyle Disorders Therapeutics Market – Competitive Landscape 124
9.1 Eli Lilly 124
9.1.1 Overview 124
9.1.2 Business Description 124
9.1.3 Major Products in the Lifestyle Disorder Therapeutics Market 125
9.2 Bayer 125
9.2.1 Overview 125
9.2.2 Business Description 126
9.2.3 Major Products in the Lifestyle Disorder Therapeutics Market 127
9.3 VIVUS Inc 127
9.3.1 Overview 127
9.3.2 Business Description 128
9.4 F. Hoffmann-La Roche Ltd. 128
9.4.1 Overview 128
9.4.2 Business Description 129
9.4.3 Major Products in the Lifestyle Disorder Therapeutics Market 129
9.5 Abbott Laboratories 130
9.5.1 Overview 130
9.5.2 Business Description 130
9.5.3 Major Products in the Lifestyle Disorder Therapeutics Market 131
9.6 GlaxoSmithKline 132
9.6.1 Overview 132
9.6.2 Business Description 132
9.6.3 Major Products in the Lifestyle Disorder Therapeutics Market 133
9.7 Shire Plc 133
9.7.1 Overview 133
9.7.2 Business Description 134
9.7.3 Major Products in the Lifestyle Disorder Therapeutics Market 134
9.8 Pfizer 135
9.8.1 Overview 135
9.8.2 Business Description 136
9.8.3 Major Products in the Lifestyle Disorder Therapeutics Market 136
9.9 Novartis 138
9.9.1 Overview 138
9.9.2 Business Description 139
9.9.3 Major Products in the Lifestyle Disorder Therapeutics Market 139
9.10 Teva Pharmaceuticals 140
9.10.1 Overview 140
9.10.2 Business Description 141
9.10.3 Major Products in the Lifestyle Disorder Therapeutics Market 141
9.11 Watson Pharmaceuticals 142
9.11.1 Overview 142
9.11.2 Business Description 143
9.11.3 Major Products in the Lifestyle Disorders Therapeutics Market 143
9.12 Merck & Co 144
9.12.1 Overview 144
9.12.2 Business Description 145
9.12.3 Major Product in the Lifestyle Disorders Therapeutics Market 146
9.13 Johnson & Johnson 146
9.13.1 Overview 146
9.13.2 Business Description 147
9.13.3 Major Products in the Lifestyle Disorders Therapeutics Market 147
9.14 Orexigen Therapeutics, Inc 147
9.14.1 Overview 147
9.14.2 Financial Overview 148
9.14.3 Major Products in the Lifestyle Disorders Therapeutic Market 148
9.15 Takeda Pharmaceutical Company Limited 148
9.15.1 Overview 148
9.15.2 Business Overview 148
9.15.3 Major Products in the Lifestyle Disorders Therapeutic Market 149
9.16 7TM Pharma 149
9.16.1 Overview 149
9.16.2 Major Products in the Lifestyle Disorders Therapeutic Market 149
10 Global Lifestyle Disorders Therapeutics Market – Strategic Consolidations 150
10.1 Mergers and Acquisitions 150
10.1.1 Deals by Geography 150
10.1.2 Deals by Indications 151
10.1.3 Deals by Year 152
10.1.4 Major Licensing Agreements, 2004-2010 152
10.2 Licensing Agreements 155
10.2.1 Licensing Agreements by Geography 155
10.2.2 Licensing Agreements by Indications 156
10.2.3 Licensing Agreements by Year 157
10.2.4 Major Licensing Agreements, 2004-2010 158
11 Global Lifestyle Disorders Market – Appendix 160
11.1 Market Definitions 160
11.2 Abbreviations 160
11.3 Research Methodology 161
11.3.1 Secondary Research 161
11.3.2 Primary Research 161
11.3.3 Forecasts 162
11.3.4 Expert Panel Validation 163
11.4 Contact Us 163
11.5 Disclaimer 163
11.6 Sources 164

1.1 List of Tables
Table 1: Erectile Dysfunction Therapeutics Market, Global, Revenue ($m), 2002–2009 15
Table 2: Erectile Dysfunction Therapeutics Market, Global, Revenue ($m), 2009–2016 15
Table 3: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2009 16
Table 4: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Therapy ($), 2009–2016 16
Table 5: Erectile Dysfunction Therapeutics Market, Global, Usage Patterns (million), 2001–2009 18
Table 6: Erectile Dysfunction Therapeutics Market, Global, Usage Patterns (million), 2009–2016 18
Table 7: Erectile Dysfunction Therapeutics Market, Global, Diseased Population (million), 2001–2009 19
Table 8: Erectile Dysfunction Therapeutics Market, Global, Diseased Population (million), 2009–2016 19
Table 9: Erectile Dysfunction Therapeutics Market, Global, Treatment Seeking Population (million), 2001–2009 21
Table 10: Erectile Dysfunction Therapeutics Market, Global, Treatment Seeking Population (million), 2009–2016 21
Table 11: Erectile Dysfunction Therapeutics Market, Global, Diagnosis Population (million), 2001–2009 23
Table 12: Erectile Dysfunction Therapeutics Market, Global, Diagnosis Population (million), 2009–2016 23
Table 13: Erectile Dysfunction Therapeutics Market, Global, Prescription Population (million), 2001–2009 25
Table 14: Erectile Dysfunction Therapeutics Market, Global, Prescription Population (million), 2009–2016 25
Table 15: Obesity Therapeutics Market, Global, Revenue ($bn), 2002–2009 31
Table 16: Obesity Therapeutics Market, Global, Revenue ($bn), 2009–2016 31
Table 17: ObesityTherapeutics Market, Annual Cost of Therapy ($), 2002–2009 32
Table 18: ObesityTherapeutics Market, Annual Cost of Therapy ($), 2009–2016 32
Table 19: ObesityTherapeutics Market, Treatment Usage Pattern (million), 2002–2009 33
Table 20: ObesityTherapeutics Market, Treatment Usage Pattern (million), 2009–2016 34
Table 21: Obesity Therapeutics Market, Global, Diseased Population (million), 2002–2009 35
Table 22: Obesity Therapeutics Market, Global, Diseased Population (million), 2009–2016 35
Table 23: Obesity Therapeutics Market, Global, Treatment Seeking Population (million), 2002–2009 36
Table 24: Obesity Therapeutics Market, Global, Treatment Seeking Population(million), 2009–2016 36
Table 25: Obesity Therapeutics Market, Global, Diagnosed Population (million), 2002–2009 37
Table 26: Obesity Therapeutics Market, Global, Diagnosed Population (million), 2009–2016 37
Table 27: Obesity Therapeutics Market, Global, Prescribed Population (million), 2002–2009 38
Table 28: Obesity Therapeutics Market, Global, Prescribed Population(million), 2009–2016 38
Table 29: Obesity Therapeutic Market, Revenue ($bn) by Geography, 2002 and 2009 40
Table 30: Obesity Therapeutic Market, Revenue ($bn) by Geography, 2009 and 2016 41
Table 31: Alopecia Therapeutics Market, Global, Revenue ($bn), 2001–2009 45
Table 32: Alopecia Therapeutics Market, Global, Revenue ($bn), 2009–2016 45
Table 33: Alopecia Therapeutics Market, Global, Annual Cost of Therapy($), 2001–2009 46
Table 34: Alopecia Therapeutics Market, Global, Annual Cost of Therapy($), 2009–2016 46
Table 35: Alopecia Areata Therapeutics Market, Global, Revenue ($m), 2002–2009 52
Table 36: Alopecia Areata Therapeutics Market, Global, Revenue ($m), 2009–2016 52
Table 37: Alopecia Areata Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2009 53
Table 38: Alopecia Therapeutics Market, Global, Annual Cost of Therapy ($), 2009–2016 53
Table 39: Alopecia Areata Therapeutics Market, Global, Usage Patterns (million), 2002–2009 54
Table 40: Alopecia Areata Therapeutics Market, Global, Usage Patterns (million), 2009–2016 55
Table 41: Alopecia Areata Therapeutics Market, Global, Diseased Population (million), 2001–2009 56
Table 42: Alopecia Areata Therapeutics Market, Global, Diseased Population (million), 2009–2016 56
Table 43: Alopecia Areata Therapeutics Market, Global, Treatment Seeking Population (million), 2001–2009 57
Table 44: Alopecia Areata Therapeutics Market, Global, Treatment Seeking Population (million), 2009–2016 57
Table 45: Alopecia Therapeutics Market, Global, Diagnosis Population (million), 2001–2009 58
Table 46: Alopecia Therapeutics Market, Global, Diagnosis Population (million), 2009–2016 58
Table 47: Alopecia Areata Therapeutics Market, Global, Prescription Population (million), 2001–2009 59
Table 48: Alopecia Areata Therapeutics Market, Global, Prescription Population (million), 2009–2016 59
Table 49: Androgenetic Alopecia Therapeutics Market, Global, Revenue ($bn), 2002–2009 64
Table 50: Androgenetic Alopecia Therapeutics Market, Global, Revenue ($bn), 2009–2016 64
Table 51: Androgenetic Alopecia Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2009 65
Table 52: Androgenetic Alopecia Therapeutics Market, Global, Annual Cost of Therapy ($), 2009–2016 65
Table 53: Androgenetic Alopecia Therapeutics Market, Global, Usage Patterns (million), 2002–2009 66
Table 54: Androgenetic Alopecia Therapeutics Market, Global, Usage Patterns (million), 2009–2016 67
Table 55: Androgenetic Alopecia Therapeutics Market, Global, Diseased Population (million), 2001–2009 68
Table 56: Androgenetic Alopecia Therapeutics Market, Global, Diseased Population (million), 2009–2016 68
Table 57: Androgenetic Alopecia Therapeutics Market, Global, Treatment Seeking Population (million), 2001–2009 69
Table 58: Androgenetic Alopecia Therapeutics Market, Global, Treatment Seeking Population (million), 2009–2016 69
Table 59: Androgenetic Alopecia Market, Global, Diagnosis Population (million), 2002–2009 70
Table 60: Androgenetic Alopecia Therapeutics Market, Global, Diagnosis Population (million), 2009–2016 70
Table 61: Androgenetic Alopecia Therapeutics Market, Global, Prescription Population (million), 2001–2009 71
Table 62: Androgenetic Alopecia Therapeutics Market, Global, Prescription Population (million), 2009–2016 71
Table 63: Smoking Cessation Therapeutics Market, Global, Revenue ($bn), 2002–2009 75
Table 64: Smoking Cessation Therapeutics Market, Global, Revenue ($bn), 2009–2016 75
Table 65: Smoking Cessation Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2009 76
Table 66: Smoking Cessation Market, Global, Annual Cost of Therapy ($), 2009–2016 76
Table 67: Smoking Cessation Therapeutics Market, Global, Usage Patterns (million), 2002–2009 78
Table 68: Smoking Cessation Market, Global, Usage Patterns (million), 2009–2016 78
Table 69: Smoking Cessation Therapeutics Market, Global, Diseased Population (million), 2001–2009 79
Table 70: Smoking Cessation Therapeutics Market, Global, Diseased Population (million), 2009–2016 79
Table 71: Smoking Cessation Therapeutics Market, Global, Treatment Seeking Population (million), 2001–2009 80
Table 72: Smoking Cessation Therapeutics Market, Global, Treatment Seeking Population (million), 2009–2016 80
Table 73: Smoking Cessation Therapeutics Market, Global, Diagnosis Population (million), 2002–2009 81
Table 74: Smoking Cessation Therapeutics Market, Global, Diagnosis Population (million), 2009–2016 81
Table 75: Smoking Cessation Therapeutics Market, Global, Prescription Population (million), 2001–2009 82
Table 76: Smoking Cessation Therapeutics Market, Global, Prescription Population (million), 2009–2016 82
Table 77: Alcohol Dependence Therapeutics Market, Global, Revenue ($m), 2002–2009 89
Table 78: Alcohol Dependence Therapeutics Market, Global, Revenue ($m), 2009–2016 89
Table 79: Alcohol Dependence Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2009 90
Table 80: Alcohol Dependence Therapeutics Market, Global, Annual Cost of Therapy ($), 2009–2016 90
Table 81: Alcohol Dependence Therapeutics Market, Global, Usage Patterns (million), 2002–2009 91
Table 82: Alcohol Dependence Therapeutics Market, Global, Usage Patterns (million), 2009–2016 92
Table 83: Alcohol Dependence Therapeutics Market, Global, Diseased Population (million), 2002–2009 93
Table 84: Alcohol Dependence Therapeutics Market, Global, Diseased Population (million), 2009–2016 93
Table 85: Alcohol Dependence Therapeutics Market, Global, Treatment Seeking Population (million), 2002–2009 94
Table 86: Alcohol Dependence Therapeutics Market, Global, Treatment Seeking Population (million), 2009–2016 94
Table 87: Alcohol Dependence Therapeutics Market, Global, Diagnosis Population (million), 2001–2009 95
Table 88: Alcohol Dependence Therapeutics Market, Global, Diagnosis Population (million), 2009–2016 95
Table 89: Alcohol Dependence Therapeutics Market, Global, Prescription Population (million), 2002–2009 96
Table 90: Alcohol Dependence Therapeutics Market, Global, Prescription Population (million), 2009–2016 96
Table 91: Erectile Dysfunction Market, Global, R&D Pipeline by Phase, 2010 100
Table 92: Obesity Therapeutics Market, Global, R&D Pipeline in Pre-clinical and Discovery Phase, 2010 105
Table 93: Obesity Therapeutics Market, Global, R&D Pipeline in Phase I, 2010 108
Table 94: Obesity Therapeutics Market, Global, R&D Pipeline in Phase II, 2010 109
Table 95: Obesity Therapeutics Market, Global, R&D Pipeline in Phase III, 2010 111
Table 96: Alopecia Therapeutics Market, Global, R&D Pipeline by Phase, 2010 113
Table 97: Smoking Cessation Therapeutics Market, Global, R&D Pipeline in Pre-clinical and Discovery Phase, 2010 114
Table 98: Smoking Cessation Therapeutics Market, Global, R&D Pipeline in Phase I, 2010 114
Table 99: Smoking Cessation Therapeutics Market, Global, R&D Pipeline in Phase II, 2010 115
Table 100:Smoking Cessation Therapeutics Market, Global, R&D Pipeline in Phase III, 2010 116
Table 101:Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Phase I, 2010 118
Table 102:Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Phase II, 2010 119
Table 103:Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Phase III, 2010 121
Table 104: Orexigen Therapeutics, Metabolic Disorders Pipeline Products, 2010 148
Table 105: Takeda Pharmaceutical, Metabolic Disorders Pipeline Products, 2010 149
Table 106: 7TM Pharma, Metabolic Disorders Pipeline Products, 2010 149

1.2 List of Figures
Figure 1: Erectile Dysfunction Therapeutics Market, Global, Revenue ($m), 2001-2016 15
Figure 2: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 16
Figure 3: Erectile Dysfunction Therapeutics Market, Global, Treatment Usage Patterns (million), 2001-2016 17
Figure 4: Erectile Dysfunction Therapeutics Market, Global, Diseased Population (million), 2001-2016 19
Figure 5: Erectile Dysfunction Therapeutics Market, Global, Treatment Seeking Population (million), 2001-2016 21
Figure 6: Erectile Dysfunction Therapeutics Market, Global, Diagnosis Population (million), 2001-2016 23
Figure 7: Erectile Dysfunction Therapeutics Market, Global, Prescription Population (million), 2001-2016 25
Figure 8: Erectile Dysfunction Therapeutic Market, Global, Anemia Market Segmentation by Geography, 2009 and 2016 27
Figure 9: Global Obesity Therapeutics Market, Global, Revenue ($bn), 2002-2016 30
Figure 10: Obesity Therapeutics Market, Annual Cost of Therapy ($), 2002–2016 32
Figure 11: ObesityTherapeutics Market, Treatment Usage Pattern (million), 2002–2016 33
Figure 12: ObesityTherapeutics Market, Diseased Population (million), 2002–2016 35
Figure 13:Obesity Therapeutics Market, Treatment Seeking Population (million), 2002–2016 36
Figure 14: ObesityTherapeutics Market, Diagnosed Population (million), 2002–2016 37
Figure 15: ObesityTherapeutics Market, Prescribed Population (million), 2002–2016 38
Figure 16: Obesity Therapeutic Market, Segmentation by Geography, 2009 and 2016 39
Figure 17: Obesity Therapeutic Market, Market Size ($bn) by Geography, 2009 and 2016 40
Figure 18: Alopecia Therapeutics Market, Global, Revenue ($bn), 2002-2016 45
Figure 19: Alopecia Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 46
Figure 20:Alopecia Therapeutics Market, Global, Segmentation by Geography, 2009 and 2016 47
Figure 21: Alopecia Therapeutics Market, Market Size by Geography, 2009 and 2016 48
Figure 22: Global Alopecia Areata Treatment Algorithm by Severity and Age 51
Figure 23: Global Alopecia Areata Therapeutics Market, Global, Revenue ($bn), 2002-2016 52
Figure 24: Alopecia Areata Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2016 53
Figure 25: Alopecia Areata Therapeutics Market, Global, Treatment Usage Patterns (million), 2001-2016 54
Figure 26: AlopeciaTherapeutics Market, Global, Diseased Population (million), 2001-2016 56
Figure 27: Alopecia Therapeutics Market, Global, Treatment Seeking Population (million), 2001-2016 57
Figure 28:Alopecia Therapeutics Market, Global, Diagnosis Population (million), 2001-2016 58
Figure 29: Alopecia Therapeutics Market, Global, Prescription Population (million), 2001-2016 59
Figure 30: Alopecia Areata Therapeutics Market, Global, Segmentation by Geography, 2009 and 2016 60
Figure 31:Alopecia Areata Therapeutics Market, Market Size by Geography, 2009 and 2016 61
Figure 32: Androgenetic Alopecia Therapeutics Market, Global, Revenue ($bn), 2002-2016 64
Figure 33: Androgenetic Alopecia Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2016 65
Figure 34: Androgenetic Alopecia Therapeutics Market, Global, Treatment Usage Patterns (million), 2001-2016 66
Figure 35: Androgenetic Alopecia Therapeutics Market, Global, Diseased Population (million), 2001-2016 68
Figure 36: Androgenetic Alopecia Therapeutics Market, Global, Treatment Seeking Population (million), 2001-2016 69
Figure 37: Androgenetic Alopecia Therapeutics Market, Global, Diagnosis Population (million), 2001-2016 70
Figure 38: Androgenetic Alopecia Therapeutics Market, Global, Prescription Population (million), 2002-2016 71
Figure 39: Androgenetic Alopecia Therapeutics Market, Global, Segmentation by Geography, 2009 and 2016 72
Figure 40: Androgenetic Alopecia Therapeutics Market, Market Size by Geography,($m), 2009 and 2016 73
Figure 41: Smoking Cessation Therapeutics Market, Global, Revenue ($bn), 2002-2016 75
Figure 42: Smoking Cessation Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2016 76
Figure 43: Smoking Cessation Therapeutics Market, Global, Treatment Usage Patterns (million), 2001-2016 77
Figure 44: Smoking Cessation Therapeutics Market, Global, Diseased Population (million), 2001-2016 79
Figure 45: Smoking Cessation Therapeutics Market, Global, Treatment Seeking Population (million), 2001-2016 80
Figure 46: Smoking Cessation Therapeutics Market, Global, Diagnosis Population (million), 2001-2016 81
Figure 47: Smoking Cessation Therapeutics Market, Global, Prescription Population (million), 2002-2016 82
Figure 48: Smoking Cessation Therapeutics Market, Segmentation by Geography, 2009 and 2016 83
Figure 49: Smoking Cessation Therapeutics Market, Market Size by Geography, 2009 and 2016 84
Figure 50: Alcohol Dependence Therapeutics Market, Global, Revenue ($m), 2002-2016 88
Figure 51: Alcohol Dependence Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2016 90
Figure 52: Alcohol Dependence Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2016 91
Figure 53: Alcohol Dependence Therapeutics Market, Global, Diseased Population (million), 2002-2016 93
Figure 54: Alcohol Dependence Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2016 94
Figure 55: Alcohol Dependence Therapeutics Market, Global, Diagnosis Population (million), 2002-2016 95
Figure 56: Alcohol Dependence Therapeutics Market, Global, Prescription Population (million), 2002-2016 96
Figure 57: Alcohol Dependence Therapeutic Market, Segmentation by Geography, 2009 and 2016 97
Figure 58: Alcohol Dependence Therapeutic Market, Market Size by Geography, 2002 to 2016 98
Figure 59: Global Lifestyle Disorders Therapeutics Market, No of M&A Deals by Indications (%), 2004-2010 150
Figure 60: Global Lifestyle Disorders Therapeutics Market, No of M&A Deals by Indications, 2004-2010 151
Figure 61: Global Lifestyle Disorders Therapeutics Market, No of M&A Deals by Indications, 2004-2010 152
Figure 62: Global Lifestyle Disorders Therapeutics Market, No of Licensing Deals by Geography, 2004-2010 155
Figure 63: Global Lifestyle Disorders Therapeutics Market, No of Licensing Deals by Indications, 2004-2010 156
Figure 64: Global Lifestyle Disorders Therapeutics Market, No of Licensing Deals by Year, 2004-2010 157